Fresh analysis reveals that individuals who stop using new slimming jabs like Mounjaro or Wegovy can put back on lost weight much more quickly than those who end conventional lifestyle plans.
Research printed in a leading medical journal demonstrates that while obese people frequently drop a large proportion of their total mass while undergoing treatment, the weight is regained at an average rate of nearly a kilo each month once they quit.
"Individuals purchasing these medications must be aware of the potential of rapid rebound weight gain when the treatment is stopped," warns lead investigator Dr. Susan Jebb.
Such speed of recovery means a return to pre-treatment weight within about 18 months.
Weighing Approaches
The study, which reviewed dozens of studies involving thousands of participants, contrasted the outcomes of the injectable medications with conventional dieting.
Scientists note that individuals who lose weight through lifestyle changes alone generally have a slower weight regain—around 0.1 kg a month—post-intervention.
The Reason for the Rapid Rebound
Experts suggest the mode of action of the injections explains the heightened rebound.
GLP-1 drugs copy a body's own chemical called GLP-1, which helps regulate hunger.
"Sustained high doses of the hormone concentrations far above than normal might result in the system to generate a reduced amount of its own natural GLP-1, and may also diminish responsiveness to its actions," explained Dr. Adam Collins, a dietetics researcher.
"Stopping of this GLP-1 'fix' means hunger is uncontrolled, making overeating much more probable."
A Lifelong Issue?
Health authorities recommend the jabs for people with obesity-related health risks, alongside recommended diet and exercise modifications.
Professionals say that, due to the likelihood of relapse, the therapy might need to be long-term.
This opinion is echoed by pharmaceutical companies, who note that the results "emphasize the chronic character of obesity," akin to managing diseases like diabetes.
User Testimonies
Users who have discontinued the jabs explain a intense resurgence of cravings.
"I experienced something activating and I was suddenly starving," said a patient.
This challenge is exacerbated if individuals have not established lasting lifestyle or habit modifications during therapy.
Growing Use
Figures indicate that a significant number of people in the UK have used weight-loss jabs in the past year, with desire remaining high.
- Adoption is more common among females than men.
- The 40s and 50s age group shows the highest level of interest.
- Many obtain the drugs through private prescriptions rather than the NHS.
In conclusion, clinicians caution that while these medications are powerful agents for shedding pounds, they are not a magic fix and lasting health benefits likely depends on integrated lifestyle changes.
